Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir

References

• Centers for Disease Control, Division of AIDS Prevention. HIV/AIDS Surveillance Report, Midyear edition through June 2001. V.. 2002; 13(1)
   Google Scholar
• Yeni PG, Hammer SM, Carpenter CC, et al, Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society—USA Panel. JAMA. 2002; 288: 222–235. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• NIH Panel to Define Principles of Therapy of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. Washington, DC, US Department of Health and Human Services. 2001; 1–48
   Google Scholar
• Bangsberg DR, Hecht FM, Charlobois ED, et al, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000; 14: 357–366. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Little SJ, Currier JS, et al, The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS. 1999; 13: 1099–1107. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Manheimer S, Friedland GH, Child C, et al, The consistency of adherence to antiretroviral therapy predicts biologic outcomes for HIV-infected persons in clinical trials. Clin Infect Dis. 2000; 34: 1115–1121. [CROSSREF]
   Google Scholar
• McCance-Katz EF, Gourevitch MN, Arnsten J, et al, Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict. 2002; 11: 271–278. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Montaner J, Hogg R, Yip B, et al, Further characterizing determinants of disease progression among HIV-1 infected patients initiating triple drug therapy. The 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos AiresArgentina 2001
   Google Scholar
• Paterson DL, Swindells S, Mohr J, et al, Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133: 21–30. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Iribarne C, Berthou F, Carlhant D, et al, Inhibition of methadone and buprenorphine n-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos. 1998; 26: 257–260. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Iribarne C, Berthou F, Baird S, et al, Involvement of cytochrome P450 3A4 enzyme in the n-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996; 9: 365–373. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hsyu PH, Lillibridge JH, Maroldo L, et al, Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between nelfinavir and methadone. 7th Conference on Retroviruses and Opportunistic Infections. Chicago, IL 2000; 91
   Google Scholar
• Altice FL, Friedland GH, Cooney EL. Nevirapine-induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 199913957–962. [CROSSREF]
   Google Scholar
• Clarke SM, Mulcahy FM, Tjia J, et al, The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001; 51: 213–217
   Google Scholar
• McCance-Katz EF, Kosten TR. Psychopharmacological treatments. Miller S, Frances R. Clinical Textbook of Addictive Disorders, 2nd ed., New York, NY, Guilford Press. 1998; 596–624
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Washington, DC, American Psychiatric Association. 2000
   Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan HK, et al, The mini-international neuropsychiatric interview (MINI): the development and validation of a structured diagnostic interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59: 22–23. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Handlesman L, Cochrane KJ, Aronson MJ, et al, Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987; 13: 293–308
   Google Scholar
• WinNonlin 1.0™. Apex, NC, Scientific Consulting, Inc. 1995
   Google Scholar
• Borenstein M, Cohen J. Statistical Power Analysis, [computer program]. 1988
   Google Scholar
• Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ, Lawrence Erlbaum Associates, Hove and London. 1988
   Google Scholar
• Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol. 1999; 47: 403–412. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Moody DE, Alburges ME, Parker RJ, et al, The involvement of cytochrome P 450 3A4 in the n-demethylation of l-alpha-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos. 1997; 25: 1347–1353. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lillibridge JH, Liang BH, Kerr, BM, et al, Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos. 1998; 26: 609–616. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Beauverie P, Taburet AM, Dessalles MC, et al, Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors. AIDS. 1998; 12: 2510–2511. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs. 2000; 59: 581–620. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kim RB, Fromm MF, Wandel C, et al, The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998; 101: 289–294. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Huang L, Wring SA, Woolley JL, et al, Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos. 2001; 29: 754–760. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zhang XQ, Schooley RT, Gerber JG. The effect of increasing alpha-1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors. J Infect Dis. 1999; 180: 1833–1837. [PUBMED], [INFOTRIEVE], [CROSSREF]
   Google Scholar
• Neff JA, Moody DE. Differential n-demethylation of l-α-acetylmethadol (LAAM) and norLAAM by cytochrome P450s 2B6, 2C18, and 3A4. Biochem Biophys Res Commun. 2001; 284: 751–756. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Gerber JG, Rosenkranz S, Segal Y, et al, Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr. 2001; 27: 153–160. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Callaghan R, Riordan JR. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem. 1993; 268: 16059–16064. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology. 2000; 92: 1392–1399. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Inturrisi CE, Colburn WA, Kaiko RF, et al, Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther. 1987; 41: 392–401. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Abramson FP.. Methadone plasma protein binding: alterations in cancer and displacement from alpha 1-acid glycoprotein. Clin Pharmacol Ther. 1982; 32: 652–658. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Garrido MJ, Aguirre C, Troconiz IF, et al, Alpha 1-acid glycoprotein (AAG) and serum protein binding of methadone in heroin addicts with abstinence syndrome. Int J Clin Pharmacol Ther. 2000; 38: 35–40. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Wu D, Otton SV, Sproule BA, et al, Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol. 1993; 35: 30–34. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Maroldo L, Manocchio S, Artenstein A, et al, Lack of effect of nelfinavir mesylate on maintenance methadone dose requirement. World AIDS Conference, DurbanSouth Africa, July. 2000
   Google Scholar
• McCance-Katz EF, Selwyn P, Farber S, et al, The protease inhibitor nelfinavir decreases methadone levels. Am J Psychiatry. 2000; 157: 481, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• ORLAAM package insert. Columbus, OH, Roxane Laboratories, Inc, Revised May. 2001
   Google Scholar
• European Agency for the Evaluation of Medicinal Products. EMEA public statement on the recommendation to suspend the marketing authorization for Orlaam (levoacetylmethadol) in the European Union. EMEA/8776/01. Available online at. www.emea.eu.int/, Accessed April 19. 2001
   Google Scholar
• Stickney JL, Keedy JD. Cardiac effects of l-alpha-acetylmethadol (LAAM) in different species. Gen Pharmacol. 1979; 10: 359–362. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Rendig SV, Amsterdam EA, Henderson GL, et al, Comparative cardiac contractile actions of six narcotic analgesics: morphine, meperidine, pentazocine, fentanyl, methadone, and l-a-acetylmethadol (LAAM). J Pharmacol Exp Ther. 1980; 215: 259–265. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Baede-van Dijk PA, Hugen PWH, Verweij-van Wissen C, et al, Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS. 2001; 15: 991–998. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zhang MH, Pithavala YK, Lee CA, et al, Apparent genetic polymorphism in nelfinavir metabolism: evaluation of clinical relevance, Abstract 2641. 12th International Symposium on Microsomes and Drug Oxidation. MontpelierFrance, July. 1998
   Google Scholar
• Eron JJ. After Athena: In search of pharmacologic correlates of nelfinavir efficacy and toxicity. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL 2001
   Google Scholar
• Wainberg M, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998; 279: 1977–1983. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar